---
run_id: halo-evidence-vs-diagnosis-validation-v9-substrate-workflow-05
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: substrate_workflow
run_number: 5
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 503
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
condition_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
output_file: model-outputs/substrate_workflow-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `substrate_workflow`, run 5 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 503, on the frozen condition packet.

## Output

**Recommendation:** I recommend the **Claim File Review**.

**Reasoning:**
The current "success" of DraftPath is heavily contaminated by performance-aware attribution and misleading proxies. According to **BK-0048-card-001**, the executive team’s current praise of the product team as "focused" and "disciplined" is likely a result of the strong quarter's outcome rather than independent causal evidence. Furthermore, your current metrics are "broad activity metrics" that look like progress but fail to disconfirm the favored story (**BK-0007-card-001**): usage is driven by managers (not users) and "lower support tickets" are actually just misclassified training requests.

The **Claim File Review** is the only option that provides a "load-bearing diagnosis" (**BK-0001-card-001**) of whether the product actually solves a problem. By inspecting whether suggestions were accepted, overridden, or "impossible to explain," you move from activity metrics to behavioral validation. This directly addresses the critical uncertainty: is DraftPath providing value, or is it a sales-driven illusion fueled by temporary pricing and roadmap promises?

**The Strongest Reason Against It:**
This approach is slow, qualitative, and small-sample. Unlike the "Commercial Cleanroom," it does not immediately test the financial elasticity of the product or its impact on bookings. It risks providing a "technical" answer (the tool is flawed) while the board is looking for a "commercial" answer (will it sell?).

**Observable Evidence That Would Change My Mind:**
I would pivot to the **Commercial Cleanroom** if you discover that the "impossible to explain" blockers in health-liability are a niche regulatory edge case rather than a systemic failure of the tool's logic. If the Claim File Review reveals that adjusters *do* find the suggestions accurate but simply lack the internal permission to use them, the problem shifts from a product-value failure (diagnosis) to a pricing/positioning failure (commercial), making the Cleanroom the higher-priority test.
